Sandoz receives positive EU opinion for biosimilar filgrastim
- Details
- Category: Novartis

Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
- Details
- Category: Financial
Johnson & Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, have announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer.
GSK and Neptunus form joint venture for the co-development of flu vaccines
- Details
- Category: GlaxoSmithKline

AstraZeneca to divest Nordic over-the-counter portfolio
- Details
- Category: AstraZeneca

Pfizer withdraws its application to change the marketing authorisation for Viagra
- Details
- Category: Pfizer

AstraZeneca granted Temporary Restraining Order in PULMICORT RESPULES patent litigation
- Details
- Category: AstraZeneca

Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants
- Details
- Category: Sanofi

More Pharma News ...
- Pfizer Launches Global Regenerative Medicine Research Unit
- SEROQUEL XR and SEROQUEL Approved in Europe for New Indications
- Tarceva brings new hope to patients with advanced non-small cell lung cancer
- Bayer's Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome
- CRESTOR® is in line with other marketed statins - new data from the JUPITER study
- Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
- GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies